Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
15.06
+0.11 (0.74%)
Dec 27, 2024, 4:00 PM EST - Market closed
Organon & Co. Revenue
Organon & Co. had revenue of $1.58B in the quarter ending September 30, 2024, with 4.15% growth. This brings the company's revenue in the last twelve months to $6.41B, up 4.21% year-over-year. In the year 2023, Organon & Co. had annual revenue of $6.26B with 1.44% growth.
Revenue (ttm)
$6.41B
Revenue Growth
+4.21%
P/S Ratio
0.60
Revenue / Employee
$640,900
Employees
10,000
Market Cap
3.88B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Option Care Health | 4.78B |
DENTSPLY SIRONA | 3.90B |
ICU Medical | 2.34B |
Haemonetics | 1.36B |
Sotera Health Company | 1.12B |
Prestige Consumer Healthcare | 1.11B |
Guardant Health | 692.26M |
Alvotech | 393.92M |
OGN News
- 9 days ago - Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - Organon: 7% Yield, 4x P/E, Big Upside Potential - Seeking Alpha
- 6 weeks ago - Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) - Seeking Alpha
- 2 months ago - Organon & Co. (OGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Organon Reports Results for the Third Quarter Ended September 30, 2024 - Business Wire
- 2 months ago - Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Business Wire
- 2 months ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
- 2 months ago - 5 Stocks to Buy for a Harris Presidency - Kiplinger